• Media type: E-Article
  • Title: Remdesivir (GS-5734) Is Efficacious in Cynomolgus Macaques Infected With Marburg Virus
  • Contributor: Porter, Danielle P; Weidner, Jessica M; Gomba, Laura; Bannister, Roy; Blair, Christiana; Jordan, Robert; Wells, Jay; Wetzel, Kelly; Garza, Nicole; Van Tongeren, Sean; Donnelly, Ginger; Steffens, Jesse; Moreau, Alicia; Bearss, Jeremy; Lee, Eric; Bavari, Sina; Cihlar, Tomas; Warren, Travis K
  • imprint: Oxford University Press (OUP), 2020
  • Published in: The Journal of Infectious Diseases
  • Language: English
  • DOI: 10.1093/infdis/jiaa290
  • ISSN: 0022-1899; 1537-6613
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title> <jats:p>Marburg virus (MARV) is a filovirus with documented human case-fatality rates of up to 90%. Here, we evaluated the therapeutic efficacy of remdesivir (GS-5734) in nonhuman primates experimentally infected with MARV. Beginning 4 or 5 days post inoculation, cynomolgus macaques were treated once daily for 12 days with vehicle, 5 mg/kg remdesivir, or a 10-mg/kg loading dose followed by 5 mg/kg remdesivir. All vehicle-control animals died, whereas 83% of animals receiving a 10-mg/kg loading dose of remdesivir survived, as did 50% of animals receiving a 5-mg/kg remdesivir regimen. Remdesivir-treated animals exhibited improved clinical scores, lower plasma viral RNA, and improved markers of kidney function, liver function, and coagulopathy versus vehicle-control animals. The small molecule remdesivir showed therapeutic efficacy in this Marburg virus disease model with treatment initiation 5 days post inoculation, supporting further assessment of remdesivir for the treatment of Marburg virus disease in humans.</jats:p>
  • Access State: Open Access